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Objectives: To compare adherence to antiretroviral therapy using
drug level monitoring and self-report and to explore the relation be-
tween these 2 methods and viral load measurements.
Methods: Sixty patients received a ﬁxed-dose combination of
nevirapine, stavudine, and lamivudine in a clinical study in Cameroon.
Adherence was assessed every 6 months until month 36 by nevirapine
minimal plasma concentration and self-report. Plasma HIV-1 viral
load was determined at the same time. Analyses included 159 com-
plete observations.
Results: The proportion of patients labeled as ‘‘adherent’’ was
signiﬁcantly lower using nevirapine monitoring (88.7%, 95%
conﬁdence interval [CI]: 82.7 to 93.2) than self-report (97.5%, CI:
93.7 to 99.3; P = 0.002). Virologic failure was associated with the
nevirapine concentration (adjusted odds ratio [aOR] = 4.43; P =
0.018) but not with the self-reported adherence (aOR = 0.84; P = 0.9).
As compared with thevirologic outcome, the sensitivity of nevirapine
level monitoring for predicting inadequate adherence was 20.5%,
the speciﬁcity was 91.7%, the positive predictive value was 44.4%,
and the negative predictive value was 78.0%. For self-report, the
respective values were 2.6%, 97.5%, 25.0%, and 75.5%.
Conclusions: Drug level monitoring provided a more reliable
estimate of adherence than self-report. This method could be used in
research settings. Operational research is required to deﬁne how to
improve the accuracy of the self-report method because it is the most
feasible method in clinical practice.
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I
nadequate adherence to antiretroviral treatment leads to
therapeutic inefﬁcacy for patients and programs (virologic,
immunologic, and clinical failure as well as emergence and
transmission of resistant viruses).
1–3 Treatment adherence
must therefore be evaluated in clinical care, in programmatic
monitoring, and in trials assessing the effectiveness of
antiretroviral regimens or adherence-improving interven-
tions.
4,5 Several methods allow adherence assessment to
medication, but none can be considered as the ‘‘gold
standard’’, with each having advantages and disadvantages.
4,6
Self-report, pharmacy reﬁll records, pill counts, visual analog
scales, and electronic drug monitors have all been assessed in
sub-Saharan Africa.
7–11 Self-report, which is simple and in-
expensive, is the most frequently used method but is notably
susceptible to memory and social desirability biases leading
to usual overestimation of adherence.
12 In contrast, adherence
measured by objective drug level monitoring has been poorly
documented in this setting.
13 We compared adherence to a
generic ﬁxed-dose combination (FDC) of nevirapine, stavu-
dine, and lamivudine (Cipla Ltd, Mumbai Central, Mumbai,
India) using the nevirapine plasma level monitoring and the
patient’s self-report and explored the relation between these
2 methods and viral load measurements in patients followed
for 36 months in a clinical study in Cameroon.
METHODS
Study Design
This study was performed among patients enrolled
between November 2002 and April 2003 in a clinical trial
designed to assess the effectiveness, safety, and quality of
a FDC of nevirapine, stavudine, and lamivudine in Yaounde ´,
the capital of Cameroon.
14,15 All the patients were eligible for
the present study if they were receiving the FDC of nevirapine,
stavudine, and lamivudine at the time of adherence and viral
load measurements. Antiretroviral therapy and care were
provided free of charge. Patients attended clinical visits every
month during the ﬁrst year and then every 2 to 3 months,
which included a physical examination and an interview. At
each visit, the patients were questioned by the treating
physicians on the number of antiretroviral doses that they did
not take during the previous 7 days and, if necessary, on the
reasons. Self-reported adherence was then calculated as the
ratio of the number of effective intakes to the number of
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judged adequate.
16 The nevirapine minimal plasma concen-
tration (Cmin) was measured 12 hours after the last intake every
6 months in patients receiving the FDC of nevirapine,
stavudine, and lamivudine using validated reverse-phase high-
performance liquid chromatography coupled with ultraviolet
detection assays.
17 Blood samples were drawn early in the
morning (between 8:00 and 10:00 AM). Patients were ques-
tioned on the time of last intake to extrapolate to 12 hours the
nevirapine concentration if the interval was different, as pre-
viously described.
18 Adherence was judged adequate if the
nevirapine concentration reached 4000 ng/mL, corresponding
to the threshold of nevirapine efﬁcacy.
19 The plasma HIV-1
viral load was determined using the Bayer branched DNA
(bDNA) HIV-1 Quantiplex assay (Bayer Diagnostics, Emery-
ville, CA) version 3.0 (limit of quantiﬁcation of 50 copies/mL)
every 6 months.
Statistical Analysis
Analyses were performed on complete observations,
deﬁned as observations with simultaneous available results of
nevirapine Cmin, self-reported adherence, and HIV-1 viral load,
after at least 12 months of treatment (except month 18).
Nevirapine Cmins in women and men were compared using the
nonparametric Mann-Whitney 2-sample test. Adherence mea-
sured by the nevirapine Cmin and self-report was compared
using the McNemar x
2 test. Multivariate random-effects
logistic regression models were used to assess the association
between nevirapine Cmin (,4000 ng/mL vs. $4000 ng/mL) or
self-reported adherence (,95% vs. $95%) and virologic
failure (HIV-1 viral load .50 copies/mL) after adjustment on
baseline covariates: age, gender, CD4 cell count, HIV-1 viral
load, clinical stage, and body mass index. A backward elim-
ination procedure was used to determine the ﬁnal model
containing only the main variable of interest (nevirapine con-
centration or self-reported adherence), together with signiﬁ-
cant covariates and potential confounders. The sensitivity,
speciﬁcity, and positive and negative predictive values of
nevirapine level monitoring or self-report as compared with
virologic outcome were calculated. The 95% conﬁdence
intervals (CIs) of percentages were estimated by the binomial
exact method. Data were analyzed using STATA 7.0 software
(Stata Corporation, College Station, TX).
RESULTS
Of 60 patients included in the initial trial, 48 (80%)
contributed to the present analysis. The other 12 patients did
not have complete observations between 12 and 36 months
after treatment initiation because of early death (6 patients),
loss to follow-up (2 patients), antiretroviral drug substitution
(1 patient with drug-related toxicity), antiretroviral drug
substitution at month 12 and then loss to follow-up (1 patient
with tuberculosis), or unavailable nevirapine Cmin at month 12
(time between last drug intake and venipuncture not recorded)
and then antiretroviral drug switch (1 patient with viral
resistance) or death (1 patient).
The 48 patients provided 159 complete observations
between months 12 and 36. The median number of
observations per patient was 4 (interquartile range [IQR]: 3
to 4 observations). These patients were predominantly women
(n = 36, 75%). At baseline, the median age was 35 years (IQR:
29 to 42 years); most patients were symptomatic (Centers for
Disease Control and Prevention [CDC] stage A [19%], stage B
[44%], and stage C [37%]); the median CD4 count was 130
cells/mm
3 (IQR: 94 to 167 cells/mm
3), and the median plasma
HIV-1 RNA level was 80,418 copies/mL (IQR: 36,720 to
202,047 copies/mL). Two women had taken nevirapine for the
prevention of HIV mother-to-child transmission at delivery
(once each). During follow-up, the HIV-1 viral load was ,50
copies/mL in 120 observations (75.5%).
The overall median nevirapine Cmin was 6453 ng/mL
(range: ,50 to 21,096 ng/mL, IQR: 5128 to 8265 ng/mL),
without signiﬁcant difference between women (6605 ng/mL
[range: ,50 to 17,331 ng/mL, IQR: 5198 to 8765 ng/mL]) and
men (6129 ng/mL [range: ,50 to 21,096 ng/mL, IQR: 5012 to
7889 ng/mL]; P = 0.5). The concentration was at least 4000
ng/mL in 141 observations (88.7%, 95% CI: 82.7 to 93.2). In
the other 18 observations (11.3%), the median concentration
was 2905 ng/mL (IQR: 52 to 3730 ng/mL). A concentration
,4000 ng/mL was signiﬁcantly associated with virologic
failure after adjustment on baseline covariates (odds ratio [OR]
= 4.43; P = 0.018; Table 1). As compared with the virologic
outcome, the sensitivity of the nevirapine level monitoring for
predicting inadequate adherence was 20.5%; the speciﬁcity
was 91.7%, the positive predictive value was 44.4%, and the
negative predictive value was 78.0% (Table 2).
The self-reported adherence was at least 95% in 155
observations (97.5%, 95% CI: 93.7 to 99.3). In contrast, the
self-reported adherence was 92.9% in 2 observations (drug
intakes forgotten), 85.7% in 1 observation (visit postponed),
or 0% in 1 observation (travel). The self-reported adherence
was signiﬁcantly higher than adherence measured by the
nevirapine level monitoring (P = 0.002). The self-reported
adherence was not associated with virologic failure (adjusted
OR = 0.84; P = 0.9; see Table 1). As compared with the
virologic outcome, the self-report had a low sensitivity for
predicting inadequate adherence (2.6%); the speciﬁcity and
the positive and negative predictive values were, respectively,
97.5%, 25.0%, and 75.5% (see Table 2).
DISCUSSION
Our study showed a high proportion of patients labeled
as ‘‘adherent’’ by nevirapine plasma level monitoring (88.7%)
TABLE 1. Association Between Nevirapine Plasma Cmin or
Self-Reported Adherence and Virologic Failure (HIV-1 Viral
Load .50 Copies/mL) From Multivariate Random-Effects
Logistic Regression Analyses
Adjusted*
OR
95%
CI P
Nevirapine Cmin
(,4000 vs. $4000 ng/mL) 4.43 1.29 to 15.23 0.018
Self-reported adherence
(,95% vs. $95%) 0.84 0.06 to 11.53 0.9
*Adjusted on baseline CD4 cell count and body mass index.
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cluded free provision of drugs and care, use of FDCs, and
support through educational and counseling sessions.
20
Adherence measured by nevirapine plasma level monitoring
was signiﬁcantly lower than self-reported adherence, however
(P = 0.002).
The nevirapine level monitoring seemed to provide
a better estimate of adherence than the self-report. Indeed,
a low nevirapine level was strongly associated with virologic
failure (OR = 4.43, 95% CI: 1.29 to 15.23; P = 0.018), as in
a cross-sectional study in Malawi (OR = 6.0, 95% CI: 2.4 to
15.3).
13 Because of the long plasma half-life of nevirapine,
a concentration .4000 ng/mL suggested probable adherence
for several days. This was a clear advantage over drugs having
a short plasma half-life, whose drug level only provides infor-
mation on adherence in the previous hours, and are therefore
more vulnerable to the ‘‘white-coat adherence’’ phenomenon
(improvement of patient’s adherence before a medical visit).
Nevertheless, it should be noted that plasma drug level is not
predictive of adherence behavior in all patients, because
nevirapine concentration may be altered (increased or de-
creased) for reasons other than adherence (eg, drug inter-
actions, individual metabolism variation, poor quality of the
drug). In our study, the quality of the FDC of nevirapine,
stavudine, and lamivudine tablets was good
14,15 and no drugs
potentially interacting with nevirapine were used. In particular,
nevirapine was replaced by efavirenz in case of antitubercu-
losis treatment (including rifampicin), and these patients were
excluded from our analysis. The genetic polymorphism that
may inﬂuence the metabolism was not investigated.
In contrast, self-reported adherence was not associated
with virologic outcome (P = 0.9). Self-report also had poorer
ability than the nevirapine level monitoring to detect non-
adherent patients (sensitivity: 2.6% vs. 20.5%), for whom
adherence-improving interventions are necessary before the
development of resistance. Identiﬁcation of nonadherent
patients is also particularly important in contexts in which
drug resistance testing is not routinely performed before
switching to second-line treatment. Interviews by persons
other than the treating physicians (eg, peer counselors, social
workers, pharmacists) are recommended to improve the esti-
mates. Training these persons to interview patients non-
judgmentally is also required.
Clearly, although drug level monitoring is a better
predictor of virologic failure than self-report, it could not be
used in routine clinical practice for many years because of its
high cost and the need for laboratory testing capacity that is
unavailable in most African countries. In contrast, this method
would provide more reliable estimates of adherence than self-
report in research settings. Interestingly, the collection of blood
spots on ﬁlter paper reduces the cost of sample storage and
forwarding.Operationalresearchis requiredto(1)compare drug
level monitoring and electronic drug monitoring, which are
known to provide better estimates of adherence than self-report;
(2)deﬁnehowtoimprovetheaccuracyoftheself-reportmethod,
because it is presently the most feasible method in clinical
practice; and (3) deﬁne new performance methods adapted to
resource-limited countries, where they are most needed.
ACKNOWLEDGMENTS
The authors thank all the patients and staff of the
Military Hospital and the Central Hospital in Yaounde ´w h o
participated in the study and the National AIDS Program,
Yaounde ´, Cameroon.
REFERENCES
1. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence
to antiretroviral therapy predicts biologic outcomes for human immuno-
deﬁciency virus-infected persons in clinical trials. Clin Infect Dis. 2002;
34:1115–1121.
2. Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence
to antiretroviral therapy and human immunodeﬁciency virus drug
resistance. Clin Infect Dis. 2003;37:1112–1118.
3. Wainberg MA, Friedland G. Public health implications of antiretroviral
therapy and HIV drug resistance. JAMA. 1998;279:1977–1983.
4. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring
antiretroviral adherence. JAcquir Immune Deﬁc Syndr. 2006;43(Suppl 1):
S79–S87.
5. Gill CJ, Hamer DH, Simon JL, et al. No room for complacency about
adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005;19:
1243–1249.
6. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;
353:487–497.
7. Orrell C, Bangsberg DR, Badri M, et al. Adherence is not a barrier to
successful antiretroviral therapy in South Africa. AIDS. 2003;17:1369–1375.
8. Lanie `ce I, Ciss M, Desclaux A, et al. Adherence to HAART and its
principal determinants in a cohort of Senegalese adults. AIDS. 2003;
17(Suppl 3):S103–S108.
TABLE 2. Performances of Nevirapine Level Monitoring and Self-Report as Compared With Viral Load
Measurement for Predicting Inadequate Adherence
Viral Load
.50 Copies/mL ,50 Copies/mL Total Se Sp PPV NPV
Nevirapine concentration 20.5% 91.7% 44.4% 78.0%
,4000 ng/mL 8 10 18
$4000 ng/mL 31 110 141
Self-report 2.6% 97.5% 25.0% 75.5%
,95% 1 3 4
$95% 38 117 155
Total 39 120 159
NPV indicates negative predictive value; PPV, positive predictive value; Se, sensitivity; Sp, speciﬁcity.
218 q 2008 Lippincott Williams & Wilkins
Kouanfack et al J Acquir Immune Deﬁc Syndr   Volume 48, Number 2, June 1, 20089. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated
measures of adherence indicate high levels of adherence to generic HIV
antiretroviral therapy in a resource-limited setting. J Acquir Immune Deﬁc
Syndr. 2004;36:1100–1102.
10. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active
antiretroviral therapy assessed by pharmacy claims predicts survival in
HIV-infected South African adults. J Acquir Immune Deﬁc Syndr. 2006;
43:78–84.
11. Bell DJ, Kapitao Y, Sikwese R, et al. Adherence to antiretroviral therapy in
patients receiving free treatment from a government hospital in Blantyre,
Malawi. J Acquir Immune Deﬁc Syndr. 2007;45:560–563.
12. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy
in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;
296:679–690.
13. van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al. Evaluation of
antiretroviral therapy results in a resource-poor setting in Blantyre,
Malawi. Trop Med Int Health. 2005;10:464–470.
14. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety
of a generic ﬁxed-dose combination of nevirapine, stavudine, and
lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre
trial. Lancet. 2004;364:29–34.
15. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Long-term safety,
effectiveness and quality of a generic ﬁxed-dose combination of
nevirapine, stavudine and lamivudine. AIDS. 2007;21:768–771.
16. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDs.
2003;17:169–177.
17. Van Heeswijk RP, Hoetelmans RM, Meenhorst PL, et al. Rapid deter-
mination of nevirapine in human plasma by ion-pair reversed-phase high-
performance liquid chromatography with ultraviolet detection. J Chromatogr
B Biomed Sci Appl. 1998;713:395–399.
18. Chaix ML, Ekouevi DK, Peytavin G, et al. Impact of nevirapine (NVP)
plasma concentration on selection of resistant virus in mothers who
received single-dose NVP to prevent perinatal human immunodeﬁciency
virus type 1 transmission and persistence of resistant virus in their infected
children. Antimicrob Agents Chemother. 2007;51:896–901.
19. Murphy R, Montaner J. Nevirapine: a review of its development, pharma-
cological proﬁle and potential for clinical use. Expert Opin Investig Drugs.
1996;5:1183–1199.
20. WHO. Antiretroviral therapy for HIV infection in adults and adolescents in
resource-limited settings: towards universal access. Recommendations for
a public health approach. 2006 revision. Available at: http://www.who.int/hiv/
pub/guidelines/artadultguidelines.pdf. 2006. Accessed October 18, 2007.
q 2008 Lippincott Williams & Wilkins 219
J Acquir Immune Deﬁc Syndr   Volume 48, Number 2, June 1, 2008 Measures of Adherence in Cameroon